Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab Beta with Chemotherapy in GD2-positive Sarcomas
NCT06669013Phase 3Recruiting
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Dinutuximab beta in rhabdomyosarcoma (RMS), Ewing sarcoma, osteosarcoma (OS), sponsored by N.N. Petrov National Medical Research Center of Oncology. Started May 2021; status: recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
rhabdomyosarcoma (RMS)Ewing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT06669013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669013.